Recordati Rare Diseases North America Email Format

Pharmaceutical ManufacturingNew Jersey, United States201-500 Employees

Recordati Rare Diseases North America (RRD) is a pharmaceutical manufacturer focused on therapies for rare diseases. Based in Bridgewater, New Jersey, it operates as the U.S. arm of the global Recordati Group, a company with roots dating back to 1926 and a broad international footprint. The organization markets medicines for rare conditions and collaborates with rare-disease communities to raise awareness, enhance diagnosis, and broaden access to treatments.

In the North American market, RRD targets patients and clinicians involved in managing rare diseases, pursuing access to therapies in the United States and Canada. A notable development in 2024 was the acquisition of Enjaymo (sutimlimab) from Sanofi, expanding its portfolio within the field of rare-disease therapeutics.

Get verified Recordati Rare Diseases North America emails free

Company overview Employee directory